UK’s Innovation Scorecard shows number of medicines used

16 October 2013

The UK’s NHS Health and Social Care Information Centre (HSCIC) has this morning published the National Institute for Health and Care Excellence (NICE) Technology Appraisals in the NHS in England Innovation Scorecard.

The scorecard is part of the reaction to the Innovation, Health and Wealth report from December 2011 which set out plans to support adoption and spread of innovation in the National Health Service (NHS). One of the actions identified in IHW aims to drive compliance with Technology Appraisals (TAs) and reduce variation by publishing information that relates to levels of compliance with NICE TAs.

Scope of the scorecard

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >